Description
IGF::OT::IGF FURNISH RADIOPHARMACEUTICAL DRUGS
First action · last action
2014-10-01 · 2016-03-10
Transactions
3
First transaction's obligation
$617,638
Base + all options value (sum of deltas)
$242,280
Extent competed
COMPETED UNDER SAP
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
4
SDVOSB flag on record
No
Parent IDV
VA24414D0448
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-10-01+$617,638= $617,638
- Mod P000012015-09-30-$375,000= $242,638
- Mod P000022016-03-10-$357= $242,280
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-10-01 | +$617,638 | $617,638 | IGF::OT::IGF FURNISH RADIOPHARMACEUTICAL DRUGS |
| Mod P00001· CHANGE ORDER | 2015-09-30 | −$375,000 | $242,638 | IGF::OT::IGF FURNISH RADIOPHARMACEUTICAL DRUGS |
| Mod P00002· FUNDING ONLY ACTION | 2016-03-10 | −$357 | $242,280 | IGF::OT::IGF FURNISH RADIOPHARMACEUTICAL DRUGS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI UW5HBQN45SS7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24420P0044 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $343,443 | FY2020 |
| VA24417J6392 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $321,980 | FY2018 |
| VA24417D0369 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $0 | FY2017 |
| VA24417J0009 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $250,629 | FY2017 |
| VA24416J5496 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $16,844 | FY2016 |
| VA24416J5500 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS | $4,875 | FY2016 |
Other recipients under 6505 from 244-NETWORK CONTRACT OFFICE 4 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24416J2870 | SOFIE CO. | 244-NETWORK CONTRACT OFFICE 4 | $69,510 | FY2016 |
| VA24416D0150 | SOFIE CO. | 244-NETWORK CONTRACT OFFICE 4 | $0 | FY2016 |
| VA24016E0159 | MCKESSON CORPORATION | 244-NETWORK CONTRACT OFFICE 4 | $15,472,688 | FY2016 |
| VA24016E0116 | MCKESSON CORPORATION | 244-NETWORK CONTRACT OFFICE 4 | $11,473,859 | FY2016 |
| VA24416J1948 | BAXALTA US INC. | 244-NETWORK CONTRACT OFFICE 4 | $35,410 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24414J3548_3600_VA24414D0448_3600 · retrieved 2026-09-27.